Home » Stocks » ATOS

Atossa Therapeutics, Inc. (ATOS)

Stock Price: $1.57 USD 0.00 (0.00%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $1.61 +0.04 (2.55%) Nov 25, 7:35 PM

Stock Price Chart

Key Info

Market Cap 16.47M
Revenue (ttm) n/a
Net Income (ttm) -12.96M
Shares Out 10.49M
EPS (ttm) -1.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $1.57
Previous Close $1.57
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.57
Day's Range 1.52 - 1.61
Day's Volume 141,515
52-Week Range 0.76 - 5.08

More Stats

Market Cap 16.47M
Enterprise Value 7.29M
Earnings Date (est) Apr 1, 2021
Ex-Dividend Date n/a
Shares Outstanding 10.49M
Float 10.46M
EPS (basic) -1.35
EPS (diluted) -1.38
FCF / Share -1.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 200,075
Short Ratio 1.79
Short % of Float 1.91%
Beta 2.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.87
Revenue n/a
Operating Income -13.01M
Net Income -12.96M
Free Cash Flow -10.86M
Net Cash 9.18M
Net Cash / Share 0.88
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -57.96%
ROE -104.16%
ROIC -1,563.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.25*
(298.09% upside)
Low
5.00
Current: $1.57
High
7.50
Target: 6.25
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue-----0.040.630.48-
Revenue Growth-----95.62%-93.65%31.28%32022.8%-
Gross Profit-----0.130.040.140.42-0.10
Operating Income-17.27-11.43-7.65-7.97-12.76-12.17-10.78-5.07-3.43
Net Income-17.24-11.40-8.12-6.37-15.76-14.66-10.78-5.08-3.44
Shares Outstanding8.504.160.970.250.160.130.090.070.05
Earnings Per Share-2.03-5.50-10.97-25.92-99.72-109.80-126.00-73.80-68.40
Operating Cash Flow-9.13-8.96-6.59-5.37-13.95-10.56-8.83-3.90-3.49
Capital Expenditures-0.01-0.11--0.01-0.130.16-0.24-0.10-0.14
Free Cash Flow-9.14-9.07-6.59-5.38-14.08-10.40-9.07-4.00-3.63
Cash & Equivalents12.6910.497.273.083.998.506.341.732.91
Total Debt0.05-----0.02-1.01
Net Cash / Debt12.6410.497.273.083.998.506.331.731.91
Assets14.4911.728.164.146.2411.7612.016.833.07
Liabilities1.332.921.231.052.502.271.411.651.51
Book Value13.168.816.943.103.749.5010.605.181.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Atossa Therapeutics, Inc.
Country United States
Employees 4
CEO Steven C. Quay

Stock Information

Ticker Symbol ATOS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATOS
IPO Date November 8, 2012

Description

Atossa Therapeutics develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.